87736-74-1 Usage
Description
4-TBDMS-HYDROXYMETHYLBROMOBENZENE, also known as (4-bromophenyl)methoxy-tert-butyl-dimethylsilane, is a colorless oil with unique chemical properties. It is a synthetic compound that features a bromobenzene core with a hydroxymethyl group and a tert-butyldimethylsilyl (TBDMS) protecting group attached to it. This structure endows it with specific reactivity and stability, making it a valuable intermediate in organic synthesis.
Uses
Used in Pharmaceutical Industry:
4-TBDMS-HYDROXYMETHYLBROMOBENZENE is used as a key intermediate in the synthesis of aromatic bisphosphonates, which are important inhibitors of geranylgeranyl diphosphate synthase. This application is crucial in the development of drugs targeting various diseases, including cancer and metabolic disorders, due to the role of geranylgeranyl diphosphate synthase in isoprenoid biosynthesis pathways.
In the synthesis of aromatic bisphosphonates, 4-TBDMS-HYDROXYMETHYLBROMOBENZENE serves as a versatile building block that can be further functionalized to create a range of bioactive compounds. The presence of the TBDMS group provides an opportunity for selective deprotection, enabling the introduction of various functional groups at the hydroxymethyl position, which can significantly influence the biological activity of the final product.
Additionally, the bromo substituent on the benzene ring allows for cross-coupling reactions, facilitating the formation of carbon-carbon bonds with other organic fragments. This reactivity is essential for the construction of complex molecular architectures found in potential drug candidates.
Overall, 4-TBDMS-HYDROXYMETHYLBROMOBENZENE is a valuable synthetic intermediate in the pharmaceutical industry, playing a critical role in the development of novel therapeutic agents targeting geranylgeranyl diphosphate synthase and other related enzymes. Its unique structural features and reactivity make it an essential component in the design and synthesis of innovative drugs with potential applications in treating various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 87736-74-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,7,7,3 and 6 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 87736-74:
(7*8)+(6*7)+(5*7)+(4*3)+(3*6)+(2*7)+(1*4)=181
181 % 10 = 1
So 87736-74-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H21BrOSi/c1-13(2,3)16(4,5)11-6-7-12(14)10(8-11)9-15/h6-8,15H,9H2,1-5H3
87736-74-1Relevant articles and documents
Charge-tagged polar phosphine ligands in Pd-catalysed reactions in aqueous and ionic media
van Zyl, Vivien L.,Muller, Alfred,Williams, D. Bradley G.
, p. 918 - 921 (2018)
A new range of polar imidazolium and phosphate-containing ligands was synthesised from readily available starting materials in high yielding multi-step transformations. These ligands were used to generate Pd catalysts for Suzuki and Heck C–C coupling reac
Iron-Catalyzed Ring Expansion of Cyclobutanols for the Synthesis of 1-Pyrrolines by Using MsONH3OTf
Zhuang, Daijiao,Gatera, Tharcisse,An, Zhenyu,Yan, Rulong
supporting information, p. 771 - 775 (2022/01/20)
The synthesis of 1-pyrrolines from cyclobutanol derivatives and an aminating reagent (MsONH3OTf) has been developed. This one-pot procedure achieves C–N bond/C═N bond formation via ring expansion. A series of 1-pyrroline derivatives are synthes
Preparation method 4 - hydroxymethylphenylboronic acid
-
Paragraph 0055-0058; 0085-0088; 0091-0094, (2021/09/08)
The invention relates to the technical field of organic synthesis. The invention specifically discloses a preparation method of 4 -hydroxymethylphenylboronic acid. To the preparation method, bromobenzyl alcohol is taken as a raw material, Grignard reagent
SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF
-
Page/Page column 74, (2020/08/22)
A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labe